Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Molecular Partners AG    MOLN   CH0256379097

MOLECULAR PARTNERS AG (MOLN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
26.5(c) 26.5(c) 26.5(c) 26.5(c) 26.5(c) Last
4 602 4 567 5 788 18 247 9 196 Volume
0.00% 0.00% 0.00% 0.00% 0.00% Change
More quotes
Financials (CHF)
Sales 2018 29,8 M
EBIT 2018 -24,5 M
Net income 2018 -25,7 M
Finance 2018 106 M
Yield 2018 -
Sales 2019 31,1 M
EBIT 2019 -30,8 M
Net income 2019 -31,6 M
Finance 2019 64,1 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 15,2x
EV / Sales2019 15,9x
Capitalization 558 M
More Financials
Company
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders.It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to... 
More about the company
Surperformance© ratings of Molecular Partners AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MOLECULAR PARTNERS AG
04/21MOLECULAR PARTNERS AG : Molecular Partners Presented Preliminary Results from th..
AC
04/21Molecular Partners presented preliminary results from the ongoing phase 2 stu..
TE
04/21MOLECULAR PARTNERS : presented preliminary results from the ongoing phase 2 stud..
AQ
04/18MOLECULAR PARTNERS AG : Shareholders of Molecular Partners AG Approve All Board ..
AC
04/18Shareholders of Molecular Partners AG approve all Board proposals at the Annu..
TE
04/18MOLECULAR PARTNERS : Shareholders of Molecular Partners AG approve all Board pro..
AQ
04/11Molecular Partners and AstraZeneca announce collaboration on Molecular Partne..
TE
04/11MOLECULAR PARTNERS AG : Molecular Partners and AstraZeneca Announce Collaboratio..
AC
04/11MOLECULAR PARTNERS : and AstraZeneca announce collaboration on Molecular Partner..
AQ
04/05Molecular Partners to present MP0310 pre-clinical data and MP0250 clinical ab..
TE
More news
Sector news : Bio Therapeutic Drugs
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/18Molecular Partners AG : Shareholders of Molecular Partners AG Approve All Boa.. 
04/11Molecular Partners gets AZ support for lung cancer trial  
04/11Molecular Partners and AstraZeneca announce collaboration on Molecular Partne.. 
04/11Molecular Partners AG : Molecular Partners and AstraZeneca Announce Collabora.. 
03/21Molecular Partners Publishes Invitation to Annual General Meeting 2018  
More tweets
Qtime:21
Chart MOLECULAR PARTNERS AG
Duration : Period :
Molecular Partners AG Technical Analysis Chart | MOLN | CH0256379097 | 4-Traders
Technical analysis trends MOLECULAR PARTNERS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 39,6  CHF
Spread / Average Target 49%
EPS Revisions
Managers
NameTitle
Patrick Amstutz Chief Executive Officer & Director
William Matt Burns Chairman
Andreas Emmenegger Chief Financial Officer
Michael Tobias Stumpp Chief Scientific Officer
Andreas Harstrick Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MOLECULAR PARTNERS AG0.76%572
GILEAD SCIENCES2.88%96 094
VERTEX PHARMACEUTICALS5.53%40 153
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998